FHTX
Foghorn Therapeutics Inc.
Price Chart
Latest Quote
$4.18
+0.03 (+0.72%)
Current Price
| Previous Close | $4.15 |
| Open | $4.20 |
| Day High | $4.28 |
| Day Low | $4.14 |
| Volume | 197,431 |
Stock Information
| Shares Outstanding | 58.71M |
| Total Debt | $41.99M |
| Cash Equivalents | $183.63M |
| Revenue | $28.22M |
| Net Income | $-75.32M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $245.42M |
| EPS (TTM) | $-1.17 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $103.79M |
| Sales | $28.22M |
| Income | $-75.32M |
| Book/sh | $-1.30 |
| Cash/sh | $3.13 |
| Employees | 106 |
Financial Ratios
| Quick Ratio | 2.85 |
| Current Ratio | 2.92 |
Returns & Margins
| ROA | -21.00% |
| Gross Margin | -190.88% |
| Operating Margin | -660.33% |
| Profit Margin | -266.88% |
Ownership
| Insider Ownership | 17.94% |
| Institutional Ownership | 76.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.50 |
| P/S | 8.70 |
| P/B | -3.21 |
Analyst Data
| Recommendation | none |
| Target Price | $11.44 |
Technical Indicators
| SMA20 | $4.01 |
| SMA50 | $4.39 |
| SMA200 | $4.86 |
| RSI | 57.68 |
| ATR | 0.2103 |
| Shares Float | 27.41M |
| Short Float | 4.60% |
| Short Ratio | 9.46 |
| Volatility | 2.89 |
| Rel Volume | 1.24 |
Performance History
| Week | +0.00% |
| Month | +4.50% |
| Quarter | -16.40% |
| 6 Months | -9.91% |
| YTD | -19.46% |
| Year | -12.00% |
| 3 Years | -48.96% |
| 5 Years | -64.99% |
| 10 Years | -76.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $4.18 | 202,300 |
| 2026-06-18 | $4.15 | 191,100 |
| 2026-06-17 | $4.05 | 141,600 |
| 2026-06-16 | $4.01 | 87,700 |
| 2026-06-15 | $4.11 | 129,700 |
| 2026-06-12 | $4.18 | 157,700 |
| 2026-06-11 | $4.06 | 317,800 |
| 2026-06-10 | $3.85 | 161,500 |
| 2026-06-09 | $3.87 | 138,200 |
| 2026-06-08 | $3.71 | 129,700 |
| 2026-06-05 | $3.73 | 119,000 |
| 2026-06-04 | $3.74 | 136,000 |
| 2026-06-03 | $3.64 | 144,300 |
| 2026-06-02 | $3.63 | 230,400 |
| 2026-06-01 | $3.97 | 139,400 |
| 2026-05-29 | $4.28 | 104,800 |
| 2026-05-28 | $4.27 | 144,000 |
| 2026-05-27 | $4.27 | 147,800 |
| 2026-05-26 | $4.37 | 282,800 |
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
đ° Latest News
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Simply Wall St. âĸ 2026-05-11T15:02:13Z
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks âĸ 2026-05-07T14:00:09Z
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T12:50:18Z
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Zacks âĸ 2026-05-06T21:25:08Z
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks âĸ 2026-05-06T14:00:05Z
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-05T12:25:07Z
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Zacks âĸ 2026-04-01T07:52:00Z
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-03-11T21:55:01Z
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Zacks âĸ 2026-03-04T22:10:01Z
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference
MarketBeat âĸ 2026-02-14T00:03:31Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $30,909,000 | $22,602,000 | $34,155,000 | $19,228,000 |
| Operating Revenue | $30,909,000 | $22,602,000 | $34,155,000 | $19,228,000 |
| Expenses | ||||
| Total Expenses | $113,016,000 | $122,887,000 | $142,061,000 | $136,365,000 |
| Other Income Expense | $-921,000 | $1,765,000 | $2,831,000 | $2,580,000 |
| Other Non Operating Income Expenses | $3,361,000 | $4,163,000 | $2,831,000 | $2,580,000 |
| Net Non Operating Interest Income Expense | $8,745,000 | $11,900,000 | $10,875,000 | $5,675,000 |
| Operating Expense | $113,016,000 | $122,887,000 | $142,061,000 | $136,365,000 |
| General And Administrative Expense | $27,550,000 | $28,359,000 | $32,372,000 | $30,747,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Net Interest Income | $8,745,000 | $11,900,000 | $10,875,000 | $5,675,000 |
| Interest Income | $8,745,000 | $11,900,000 | $10,875,000 | $5,675,000 |
| Normalized Income | $-70,001,000 | $-84,222,000 | $-98,426,000 | $-108,882,000 |
| Net Income From Continuing And Discontinued Operation | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Total Operating Income As Reported | $-86,389,000 | $-102,683,000 | $-107,906,000 | $-117,137,000 |
| Net Income Common Stockholders | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Net Income | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Net Income Including Noncontrolling Interests | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Net Income Continuous Operations | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Pretax Income | $-74,283,000 | $-86,620,000 | $-94,200,000 | $-108,882,000 |
| Special Income Charges | $-4,282,000 | $-2,398,000 | $0 | $0 |
| Interest Income Non Operating | $8,745,000 | $11,900,000 | $10,875,000 | $5,675,000 |
| Operating Income | $-82,107,000 | $-100,285,000 | $-107,906,000 | $-117,137,000 |
| Per Share | ||||
| Diluted EPS | $-1.18 | $-1.58 | $-2.34 | $-2.62 |
| Basic EPS | $-1.18 | $-1.58 | $-2.34 | $-2.62 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-74,493,000 | $-94,767,000 | $-104,455,000 | $-113,816,000 |
| Total Unusual Items | $-4,282,000 | $-2,398,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-4,282,000 | $-2,398,000 | $0 | $0 |
| Reconciled Depreciation | $3,332,000 | $3,120,000 | $3,451,000 | $3,321,000 |
| EBITDA (Bullshit earnings) | $-78,775,000 | $-97,165,000 | $-104,455,000 | $-113,816,000 |
| EBIT | $-82,107,000 | $-100,285,000 | $-107,906,000 | $-117,137,000 |
| Diluted Average Shares | $62,980,959 | $54,899,432 | $41,974,484 | $41,591,433 |
| Basic Average Shares | $62,980,959 | $54,899,432 | $41,974,484 | $41,591,433 |
| Diluted NI Availto Com Stockholders | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Other Special Charges | $-1,632,000 | - | - | - |
| Write Off | $5,914,000 | $2,398,000 | $0 | - |
| Research And Development | $85,466,000 | $94,528,000 | $109,689,000 | $105,618,000 |
| Selling General And Administration | $27,550,000 | $28,359,000 | $32,372,000 | $30,747,000 |
| Other Gand A | $10,135,000 | $11,234,000 | $11,806,000 | $12,504,000 |
| Salaries And Wages | $17,415,000 | $17,125,000 | $20,566,000 | $18,243,000 |
| Tax Provision | - | $0 | $4,226,000 | $0 |
| Impairment Of Capital Assets | - | $2,398,000 | $0 | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-108,500,000 | $-45,528,000 | $-77,190,000 | $112,000 |
| Total Assets | $198,103,000 | $283,982,000 | $285,916,000 | $404,883,000 |
| Total Non Current Assets | $34,868,000 | $34,381,000 | $45,735,000 | $53,484,000 |
| Other Non Current Assets | $2,004,000 | $1,776,000 | $2,823,000 | $4,087,000 |
| Current Assets | $163,235,000 | $249,601,000 | $240,181,000 | $351,399,000 |
| Other Current Assets | $3,091,000 | $5,854,000 | $6,124,000 | $5,601,000 |
| Restricted Cash | $1,250,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $158,894,000 | $243,747,000 | $234,057,000 | $345,798,000 |
| Cash And Cash Equivalents | $80,876,000 | $55,454,000 | $80,336,000 | $52,214,000 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $41,270,000 | $37,131,000 | $45,073,000 | $51,507,000 |
| Long Term Debt And Capital Lease Obligation | $40,347,000 | $28,064,000 | $36,555,000 | $45,537,000 |
| Current Debt And Capital Lease Obligation | $923,000 | $9,067,000 | $8,518,000 | $5,970,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $306,603,000 | $329,510,000 | $363,106,000 | $404,771,000 |
| Total Non Current Liabilities Net Minority Interest | $246,865,000 | $262,521,000 | $304,670,000 | $349,566,000 |
| Other Non Current Liabilities | $556,000 | - | - | $29,000 |
| Non Current Deferred Liabilities | $205,962,000 | $234,457,000 | $268,115,000 | $304,000,000 |
| Current Liabilities | $59,738,000 | $66,989,000 | $58,436,000 | $55,205,000 |
| Other Current Liabilities | $400,000 | $1,000 | $36,000 | $318,000 |
| Current Deferred Liabilities | $43,192,000 | $45,606,000 | $34,550,000 | $32,820,000 |
| Payables And Accrued Expenses | $9,302,000 | $7,573,000 | $10,985,000 | $11,354,000 |
| Payables | $4,266,000 | $3,785,000 | $6,934,000 | $5,414,000 |
| Accounts Payable | $4,266,000 | $3,785,000 | $6,260,000 | $5,414,000 |
| Total Tax Payable | - | $0 | $674,000 | $0 |
| Income Tax Payable | - | $0 | $674,000 | $0 |
| Equity | ||||
| Common Stock Equity | $-108,500,000 | $-45,528,000 | $-77,190,000 | $112,000 |
| Total Equity Gross Minority Interest | $-108,500,000 | $-45,528,000 | $-77,190,000 | $112,000 |
| Stockholders Equity | $-108,500,000 | $-45,528,000 | $-77,190,000 | $112,000 |
| Gains Losses Not Affecting Retained Earnings | $24,000 | $135,000 | $-826,000 | $-3,986,000 |
| Other Equity Adjustments | $24,000 | $135,000 | $-826,000 | $-3,986,000 |
| Retained Earnings | $-632,467,000 | $-558,184,000 | $-471,564,000 | $-373,138,000 |
| Other | ||||
| Ordinary Shares Number | $56,657,329 | $55,594,131 | $42,282,040 | $41,803,436 |
| Share Issued | $56,657,329 | $55,594,131 | $42,282,040 | $41,803,436 |
| Tangible Book Value | $-108,500,000 | $-45,528,000 | $-77,190,000 | $112,000 |
| Invested Capital | $-108,500,000 | $-45,528,000 | $-77,190,000 | $112,000 |
| Working Capital | $103,497,000 | $182,612,000 | $181,745,000 | $296,194,000 |
| Capital Lease Obligations | $41,270,000 | $37,131,000 | $45,073,000 | $51,507,000 |
| Total Capitalization | $-108,500,000 | $-45,528,000 | $-77,190,000 | $112,000 |
| Additional Paid In Capital | $523,937,000 | $512,515,000 | $395,196,000 | $377,232,000 |
| Capital Stock | $6,000 | $6,000 | $4,000 | $4,000 |
| Common Stock | $6,000 | $6,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $205,962,000 | $234,457,000 | $268,115,000 | $304,000,000 |
| Long Term Capital Lease Obligation | $40,347,000 | $28,064,000 | $36,555,000 | $45,537,000 |
| Current Deferred Revenue | $43,192,000 | $45,606,000 | $34,550,000 | $32,820,000 |
| Current Capital Lease Obligation | $923,000 | $9,067,000 | $8,518,000 | $5,970,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,921,000 | $4,742,000 | $4,347,000 | $4,743,000 |
| Current Accrued Expenses | $5,036,000 | $3,788,000 | $4,051,000 | $5,940,000 |
| Net PPE | $32,864,000 | $32,605,000 | $42,912,000 | $49,397,000 |
| Accumulated Depreciation | $-7,005,000 | $-15,084,000 | $-12,017,000 | $-8,611,000 |
| Gross PPE | $39,869,000 | $47,689,000 | $54,929,000 | $58,008,000 |
| Leases | $0 | $17,023,000 | $17,239,000 | $17,123,000 |
| Other Properties | $38,984,000 | $29,760,000 | $36,760,000 | $39,970,000 |
| Machinery Furniture Equipment | $885,000 | $906,000 | $930,000 | $915,000 |
| Buildings And Improvements | $30,949,000 | $22,641,000 | $29,956,000 | $34,086,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $78,018,000 | $188,293,000 | $153,721,000 | $293,584,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-86,149,000 | $-101,312,000 | $-119,330,000 | $192,402,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-86,099,000 | $-100,406,000 | $-118,106,000 | $193,612,000 |
| Cash Flow From Continuing Operating Activities | $-86,099,000 | $-100,406,000 | $-118,106,000 | $193,612,000 |
| Operating Gains Losses | $31,000 | - | $3,000 | $6,000 |
| Investing Activities | ||||
| Capital Expenditure | $-50,000 | $-906,000 | $-1,224,000 | $-1,210,000 |
| Investing Cash Flow | $112,040,000 | $-29,904,000 | $144,450,000 | $-244,322,000 |
| Cash Flow From Continuing Investing Activities | $112,040,000 | $-29,904,000 | $144,450,000 | $-244,322,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $540,000 | $103,401,000 | $0 | $0 |
| Financing Cash Flow | $1,023,000 | $105,428,000 | $1,778,000 | $1,763,000 |
| Cash Flow From Continuing Financing Activities | $1,023,000 | $105,428,000 | $1,778,000 | $1,763,000 |
| Net Common Stock Issuance | $540,000 | $103,401,000 | $0 | $0 |
| Common Stock Issuance | $540,000 | $103,401,000 | $0 | $0 |
| Net Other Financing Charges | - | $-585,000 | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $9,000 | $860,000 | $3,551,000 | $0 |
| End Cash Position | $84,126,000 | $57,162,000 | $82,044,000 | $53,922,000 |
| Beginning Cash Position | $57,162,000 | $82,044,000 | $53,922,000 | $102,869,000 |
| Changes In Cash | $26,964,000 | $-24,882,000 | $28,122,000 | $-48,947,000 |
| Proceeds From Stock Option Exercised | $483,000 | $2,612,000 | $1,778,000 | $1,763,000 |
| Net Investment Purchase And Sale | $112,090,000 | $-28,998,000 | $145,674,000 | $-243,112,000 |
| Sale Of Investment | $243,337,000 | $232,472,000 | $219,575,000 | $166,233,000 |
| Purchase Of Investment | $-131,247,000 | $-261,470,000 | $-73,901,000 | $-409,345,000 |
| Net PPE Purchase And Sale | $-50,000 | $-906,000 | $-1,224,000 | $-1,210,000 |
| Purchase Of PPE | $-50,000 | $-906,000 | $-1,224,000 | $-1,210,000 |
| Change In Working Capital | $-32,140,000 | $-32,266,000 | $-41,879,000 | $281,546,000 |
| Change In Other Working Capital | $-30,909,000 | $-22,602,000 | $-34,155,000 | $-14,227,000 |
| Change In Other Current Liabilities | $-6,743,000 | $-7,942,000 | $-7,514,000 | $-6,975,000 |
| Change In Payables And Accrued Expense | $2,685,000 | $-3,039,000 | $-951,000 | $3,055,000 |
| Change In Accrued Expense | $2,204,000 | $-564,000 | $-1,797,000 | $1,441,000 |
| Change In Payable | $481,000 | $-2,475,000 | $846,000 | $1,614,000 |
| Change In Account Payable | $481,000 | $-2,475,000 | $846,000 | $1,614,000 |
| Change In Prepaid Assets | $2,827,000 | $1,317,000 | $741,000 | $-307,000 |
| Other Non Cash Items | $2,574,000 | $5,682,000 | $5,210,000 | $4,580,000 |
| Stock Based Compensation | $10,399,000 | $11,893,000 | $16,186,000 | $14,336,000 |
| Asset Impairment Charge | $5,914,000 | $2,398,000 | $0 | - |
| Amortization Of Securities | $-1,926,000 | $-4,613,000 | $-2,651,000 | $-1,295,000 |
| Depreciation Amortization Depletion | $3,332,000 | $3,120,000 | $3,451,000 | $3,321,000 |
| Depreciation And Amortization | $3,332,000 | $3,120,000 | $3,451,000 | $3,321,000 |
| Gain Loss On Sale Of PPE | $31,000 | $0 | $3,000 | $6,000 |
| Net Income From Continuing Operations | $-74,283,000 | $-86,620,000 | $-98,426,000 | $-108,882,000 |
| Change In Receivables | - | - | $0 | $300,000,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Changes In Account Receivables | - | - | - | $300,000,000 |
| Depreciation | - | - | - | $3,321,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-22